San Diego, CA -- (SBWIRE) -- 10/02/2013 -- An investigation on behalf of investors of Prosensa Holding NV (NASDAQ:RNA) shares over potential securities laws violations by Prosensa Holding and certain of its directors and officers was announced in connection with certain statements concerning its initial public offering on June 28, 2013.

Investors who purchased shares of Prosensa Holding NV (NASDAQ:RNA) have certain options and should contact the Shareholders Foundation at mail(at)shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Prosensa Holding NV (NASDAQ:RNA) concerning whether a series of statements by Prosensa Holding regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Prosensa Holding NV reported that its annual Total Revenue declined from $8.69 million in 2011 to $7.85 million in 2012 while its respective Net Loss decreased from $11.58 million to $9.89 million. For the first quarter in 2013 Prosensa Holding NV reported quarterly Revenue of $2.4 million, compared to $1.97 million in the first quarter in 2012 and for the second quarter in 2013 Prosensa Holding NV reported quarterly Revenue of $1.98 million, compared to $1.25 million in 2012.

In June 2013 Prosensa Holding NV went public. Shares of Prosensa Holding NV (NASDAQ:RNA) rose from $19.25 per share in early July 2013 to $3.28 per share on August 1, 2013.

Then on Sept. 20, 2013, GlaxoSmithKline and Prosensa Holding NV announced that the Phase III clinical study of drisapersen, an investigational antisense oligonucleotide, for the treatment of Duchenne Muscular Dystrophy patients with an amenable mutation, did not meet the primary endpoint of a statistically significant improvement in the 6 Minute Walking Distance test compared to placebo.

Shares of Prosensa Holding NV (NASDAQ:RNA) dropped from $24.00 per share on Sept. 19, 2013, to as low as $5.82 per share on Sept. 25, 2013.

On Oct. 1, 2013, NASDA:RNA shares closed at $7.05 per share.

Those who purchased shares of Prosensa Holding NV have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Trevor Allen
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com